A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Colorectal Cancer

Interventions

DRUG: VVD-133214
DRUG: Pembrolizumab
DRUG: Bevacizumab

Sponsor

Vividion Therapeutics, Inc.